These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35835755)

  • 1. Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya.
    Dabee S; Mugo N; Mudhune V; McLellan-Lemal E; Peacock S; O'Connor S; Njoroge B; Nyagol B; Thurman AR; Ouma E; Ridzon R; Wiener J; Haugen HS; Gasper M; Feng C; Allen SA; Doncel GF; Jaspan HB; Heffron R;
    Sci Rep; 2022 Jul; 12(1):12040. PubMed ID: 35835755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
    Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
    PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
    Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
    PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
    Thurman AR; Brache V; Cochon L; Ouattara LA; Chandra N; Jacot T; Yousefieh N; Clark MR; Peet M; Hanif H; Schwartz JL; Ju S; Marzinke MA; Erikson DW; Parikh U; Herold BC; Fichorova RN; Tolley E; Doncel GF
    PLoS One; 2022; 17(10):e0275794. PubMed ID: 36215267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
    Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
    Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.
    Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
    Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
    Ouattara LA; Thurman AR; Jacot TA; Cottrell M; Sykes C; Blake K; Fang X; Ju S; Vann NC; Schwartz J; Doncel GF
    J Acquir Immune Defic Syndr; 2022 Jan; 89(1):87-97. PubMed ID: 34878438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
    Villegas G; Calenda G; Ugaonkar S; Zhang S; Kizima L; Mizenina O; Gettie A; Blanchard J; Cooney ML; Robbiani M; Fernández-Romero JA; Zydowsky TM; Teleshova N
    PLoS One; 2016; 11(7):e0159332. PubMed ID: 27428377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
    PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
    Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.
    Ursell LK; Gunawardana M; Chang S; Mullen M; Moss JA; Herold BC; Keller MJ; McDonald D; González A; Knight R; Baum MM
    Antiviral Res; 2014 Feb; 102():87-94. PubMed ID: 24361269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
    Heffron R; McClelland RS; Balkus JE; Celum C; Cohen CR; Mugo N; Bukusi E; Donnell D; Lingappa J; Kiarie J; Fiedler T; Munch M; Fredricks DN; Baeten JM;
    Lancet HIV; 2017 Oct; 4(10):e449-e456. PubMed ID: 28732773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
    Velloza J; Heffron R
    Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
    Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
    Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP.
    Morris S; Cottrell M; Rawlings SA; Peterson S; Karris M; Pacheco D; Chaillon A; Kay A; Chow K; Anderson PL; Gianella S; Blumenthal J
    J Acquir Immune Defic Syndr; 2022 Apr; 89(4):390-395. PubMed ID: 35202047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
    Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
    Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.